Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors

NCT ID: NCT00726687

Last Updated: 2012-07-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-06-30
• Study Completion Date: 2013-06-30

Brief Summary

This is a phase 1b study of Indibulin in combination with Capecitabine in advanced solid tumors.

Detailed Description

The primary objective of the trial is to determine the maximum tolerated dose (MTD) and optimal dosing schedule of indibulin in combination with capecitabine in subjects diagnosed as having advanced solid tumors.

Secondary objectives include the determination of dose-limiting toxicity (DLT), safety and tolerability, and preliminary activity of this combination. In addition, biological activity of indibulin in combination with capecitabine will be evaluated.

Single arm, open label, Phase Ib, dose-escalation study of indibulin in combination with capecitabine in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with capecitabine is considered medically acceptable.

3 subjects will be treated at each dose level. When DLT occurs in 2 or more of 6 or fewer subjects, MAD has been reached and the dose will be reduced to the previous dosing level, which will be considered the MTD.

Conditions

Advanced Solid Tumors

Keywords

Cancer; Indibulin; Capecitabine; Xeloda

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

single

Single arm designed to elicit Maximum Tolerated Dose

Group Type: EXPERIMENTAL

indibulin

Intervention Type: DRUG

indibulin, dose escalation, 400-600 mg taken twice every day

capecitabine

Intervention Type: DRUG

capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle

Interventions

indibulin

indibulin, dose escalation, 400-600 mg taken twice every day

Intervention Type: DRUG

capecitabine

capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle

Intervention Type: DRUG

Other Intervention Names

Xeloda

Eligibility Criteria

Inclusion Criteria

1. Subjects with advanced, histologically confirmed solid tumors for whom treatment with capecitabine is considered medically acceptable

2. ≥18 years of age

3. ECOG performance score ≤2 (see Appendix 2)

4. Eligible subjects MUST have at least one measurable lesion as defined by RECIST guidelines (see Appendix 3). Measurable lesions MUST NOT have been in a previously irradiated field or injected with biological agents.

5. Life-expectancy ≥12 weeks

6. No more than 2 prior chemotherapy regimens for metastatic disease

7. Subjects on prophylactic anticoagulation (i.e., low-dose warfarin) are eligible provided the coagulation parameter levels are as follows: prothrombin time (INR of prothrombin time) <1.1× institutional ULN

8. Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted <2 weeks prior to Study Day 1:

• Creatinine ≤1.5 × upper limit of normal (ULN) OR a calculated creatinine clearance ≥1.50 cc/min (See Appendix 6 for calculation method)
• Total bilirubin ≤1.5×ULN
• Alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5×ULN (<5×ULN for patients presenting with liver involvement)
• White blood cell count ≥3.0×109/L
• Absolute neutrophil count (ANC) ≥1.5×109/L
• Platelets ≥100×109/L
• Hemoglobin ≥10 g/dL

9. Written informed consent in compliance with ZIOPHARM policies and the Institutional Review Board (IRB) having jurisdiction over the site

10. Ability and willingness to undergo multiple venous punctures for serum PK sampling

11. For the second phase of the trial (expanded cohort of 10), only capecitabine-naïve subjects will be included; prior therapy with 5-FU will be allowed

12. Each man and woman of childbearing potential must agree to use a reliable method of contraception during the study and for 3 months following his or her last dose of study drug

Exclusion Criteria

1. New York Heart Association (NYHA) functional class ≥3 or myocardial infarction within 6 months (see Appendix 4)

2. Severe renal impairment (creatinine clearance below 30 mL/min)

3. Known dihydropyrimidine dehydrogenase deficiency (DPD)

4. Any evidence of bleeding diathesis or coagulopathy

5. International normalized ration (INR) >1.5, unless the subject is on full-dose warfarin

6. Subjects on full-dose anticoagulants (e.g., warfarin) are eligible provided that both of the following criteria are met:

• The subject must have an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular-weight heparin
• The subject must not have any active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)

7. Pregnancy and/or lactation. To be enrolled, each woman of childbearing potential must have a negative pregnancy test, which will be repeated at the end of the study.

8. Uncontrolled systemic infection (documented with microbiological studies)

9. Anticancer chemotherapy or immunotherapy within 4 weeks of study entry or at any time during the study or investigational drug therapy outside of this trial during or within 4 weeks of study entry

10. Mitomycin C or nitrosureas should not be given within 6 weeks of study entry.

11. Radiotherapy within 3 weeks of study entry or at any time during the study. For target lesions that have been radiated within 3 months of study entry, only those lesions with documented progression post radiation will be allowed.

12. Surgery within 4 weeks of start of study drug dosing, excluding tumor biopsy for pharmacodynamic parameters

13. History of an invasive second primary malignancy diagnosed within the previous 3 years except for Stage I endometrial/cervical carcinoma or prostate carcinoma treated surgically, and non-melanoma skin cancer

14. Substance abuse or medical, psychological or social conditions that may interfere with the subject's participation in the study or the evaluation of study results

15. Any condition that is unstable or could jeopardize the safety of the subject and his/her compliance with study protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Alaunos Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jonathan Lewis, MD

Role: STUDY_CHAIR

Alaunos Therapeutics

Locations

Indianapolis, Indiana, United States

Las Vegas, Nevada, United States

Vancouver, Washington, United States

Countries

United States

References

Kapoor S, Srivastava S, Panda D. Indibulin dampens microtubule dynamics and produces synergistic antiproliferative effect with vinblastine in MCF-7 cells: Implications in cancer chemotherapy. Sci Rep. 2018 Aug 17;8(1):12363. doi: 10.1038/s41598-018-30376-y.

Reference Type: DERIVED

PMID: 30120268 (View on PubMed)

Other Identifiers

IBL1005

Identifier Type: -

Identifier Source: org_study_id